Inhibiting G6PD by quercetin promotes degradation of EGFR T790M mutation

Inhibiting G6PD by quercetin promotes degradation of EGFR T790M mutation

Summary: EGFRT790M mutation causes resistance to the first-generation tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancer (NSCLC). However, the therapeutic options for sensitizing first TKIs and delaying the emergence of EGFRT790M mutant are limited. In this study, we show...

Full description

Bibliographic Details
Main Authors:	Zehe Ge, Miao Xu, Yuqian Ge, Guang Huang, Dongyin Chen, Xiuquan Ye, Yibei Xiao, Hongyu Zhu, Rong Yin, Hua Shen, Gaoxiang Ma, Lianwen Qi, Guining Wei, Dongmei Li, Shaofeng Wei, Meng Zhu, Hongxia Ma, Zhumei Shi, Xiuxing Wang, Xin Ge, Xu Qian
Format:	Article
Language:	English
Published:	Elsevier 2023-11-01
Series:	Cell Reports
Subjects:	CP: Cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S2211124723014298

Similar Items

EGFR T790M: revealing the secrets of a gatekeeper
by: Ko B, et al.
Published: (2017-10-01)

Quercetin and polycystic ovary syndrome
by: Congshun Ma, et al.
Published: (2022-12-01)

Identification of a Rare EGFR T790I Mutation in Lung Adenocarcinoma Sensitive to Osimertinib
by: Yu Wang, et al.
Published: (2021-10-01)

EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation.
by: Teppei Yamada, et al.
Published: (2013-01-01)

Deciphering mechanisms of acquired T790M mutation after EGFR inhibitors for NSCLC by computational simulations
by: Bin Zou, et al.
Published: (2017-07-01)

Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC
by: Jiameng Lu, et al.
Published: (2024-01-01)

Rebiopsy with Thoracoscopy under Local Anesthesia for the Detection of EGFR T790M Mutation
by: Asako Matsuda, et al.
Published: (2019-12-01)

Discovery of a Novel, Selective and Irreversible Inhibitor (Abivertinib) of Mutated EGFR and T790M-induced Resistance for the Treatment of NSCLC
by: Long Mao, et al.
Published: (2020-06-01)

Anlotinib plus chemotherapy for T790M‐negative EGFR‐mutant non‐sqNSCLC resistant to TKIs: A multicenter phase 1b/2 trial
by: Juan Li, et al.
Published: (2022-12-01)

Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
by: Lin-Peng Zheng, et al.
Published: (2018-11-01)

An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
by: Shang-Gin Wu, et al.
Published: (2020-09-01)

Case report: Neuroendocrine breast carcinoma with a germline EGFR T790M mutation
by: Olivia A. Sagan, et al.
Published: (2023-05-01)

Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation
by: Asim Joshi, et al.
Published: (2022-08-01)

Research Progress of EGFR T790M Mutation in Non-small Cell Lung Cancer
by: HOU Ran, et al.
Published: (2020-06-01)

Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
by: Kejing Tang, et al.
Published: (2019-02-01)

EGFR Thr790Leu as a Potential Resistance Mechanism to First-Generation EGFR Tyrosine Kinase Inhibitor May Respond to Osimertinib in Patients With Lung Adenocarcinoma
by: Chan Xiang, PhD, et al.
Published: (2021-07-01)

The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors
by: Ikei S. Kobayashi, MD, PhD, et al.
Published: (2024-01-01)

Droplet Digital PCR as a Molecular Tool for the Detection of the EGFR T790M Mutation in NSCLC Patients with the EGFR Activating Mutations
by: Durgut S, et al.
Published: (2024-03-01)

Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer
by: Takeshi Masuda, et al.
Published: (2023-11-01)

Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR-Activating Mutation In Non- Small Cell Lung Cancer
by: Gao X, et al.
Published: (2019-11-01)

Clinical impact of subclonal EGFR T790M mutations in advanced-stage EGFR-mutant non-small-cell lung cancers
by: Tereza Vaclova, et al.
Published: (2021-03-01)

Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib
by: Yuko Oya, et al.
Published: (2021-01-01)

In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common features
by: Xiang M, et al.
Published: (2013-08-01)

Molecular docking analysis on the designed benzimidazole derivatives as EGFR inhibitors: comparison between EGFR wild-type (EGFRWT) and T790M mutant
by: Nurul Awani Syazzira Jalil,, et al.
Published: (2023)

A case of EGFR mutation-positive lung adenocarcinoma in which the T790M allele fraction was increased by repeated EGFR-TKI treatment
by: Hideharu Kimura, et al.
Published: (2019-11-01)

Optimizing Sequential Treatment With EGFR Tyrosine Kinase Inhibitor With a Simulation of the T790M Mutation Rate in EGFR–Mutated Lung Cancer
by: Naoki Haratake, MD, PhD, et al.
Published: (2020-11-01)

The Presence of EGFR T790M in TKI-Naïve Lung Cancer Samples of Patients Who Developed a T790M-Positive Relapse on First or Second Generation TKI Is Rare
by: Weiting Li, et al.
Published: (2022-07-01)

The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations
by: Akihiro Yoshimura, et al.
Published: (2018-12-01)

Hypoxanthine phosphoribosyl transferase 1 metabolizes temozolomide to activate AMPK for driving chemoresistance of glioblastomas
by: Jianxing Yin, et al.
Published: (2023-09-01)

Sputum cell‐free DNA: Valued surrogate sample for the detection of EGFR exon 20 p.T790M mutation in patients with advanced lung adenocarcinoma and acquired resistance to EGFR‐TKIs
by: Zheng Wang, et al.
Published: (2021-05-01)

Differential prognostic value of tumor and plasma T790M mutations in EGFR TKI-treated advanced NSCLC
by: Pi-Hung Tung, et al.
Published: (2024-01-01)

Monitoring of Plasma EGFR Mutations during Osimertinib Treatment for NSCLC Patients with Acquired T790M Mutation
by: Kana Watanabe, et al.
Published: (2023-08-01)

Identification of Candidate Biomarkers for EGFR-T790M Drug-resistant  Gene Mutation in Advanced Lung Adenocarcinoma
by: Lijuan CHEN, et al.
Published: (2020-11-01)

Diagnostic accuracy of droplet digital PCR for detection of EGFR T790M mutation in circulating tumor DNA
by: Zhang R, et al.
Published: (2018-05-01)

The ratio of T790M to EGFR-activating mutation predicts response of osimertinib in 1st or 2nd generation EGFR-TKI-refractory NSCLC
by: Motohiro Tamiya, et al.
Published: (2021-05-01)

EGFR tyrosine kinase inhibitor HS-10182 increases radiation sensitivity in non-small cell lung cancers with EGFR T790M mutation
by: Yang Chen, et al.
Published: (2018-03-01)

EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer
by: Tomoaki Sonoda, et al.
Published: (2018-01-01)

Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC.
by: Zhijie Wang, et al.
Published: (2014-01-01)

Anlotinib can overcome acquired resistance to EGFR‐TKIs via FGFR1 signaling in non‐small cell lung cancer without harboring EGFR T790M mutation
by: Zengzhi Lian, et al.
Published: (2020-07-01)

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
by: Qiufan Zheng, et al.
Published: (2020-02-01)